VEGFC ANTIBODY TREATMENT: A NEW DIFFERENTIATION THERAPY FOR AML
EHA Learning Center, Kim Kampen, 214637
BIALLELIC INACTIVATION OF ATM AND BIRC3 IN DEL(11Q) CELLS DRIVES GENOMIC INSTABILITY AND TUMOR EXPANSION IN CRISPR/CAS9-GENERATED MODELS OF CHRONIC LYMPHOCYTIC LEUKEMIA
EHA Learning Center, Miguel Quijada Alamo, 214653
CD20 IS A DIRECT REGULATOR OF B-CELL RECEPTOR SIGNALING IN THE MICROENVIRONMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
EHA Learning Center, Gabriela Pavlasova, 214654
THE PHILADELPHIA-LIKE SUBTYPE IN CHILDREN WITH FIRST RELAPSE OF B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA: A STUDY OF THE GERMAN ALL-REZ BFM 2002 TRIAL
EHA Learning Center, Malwine Pogodzinski, 215237
HUMAN T CELL ACUTE LYMPHOBLASTIC LEUKEMIA DEVELOPS HYPOXIA-RELATED CHEMORESISTANCE THROUGH HIF1Α AND MTOR PATHWAY INTERACTIONS
EHA Learning Center, Lucine Fahy, 215238
THE CELL SURFACE PROTEIN VANIN-2 IDENTIFIES AGGRESSIVE SUBTYPES OF CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA
EHA Learning Center, Virginia Rodriguez Martinez, 215253
NILOTINIB COMBINED WITH LOWER-INTENSITY CHEMOTHERAPY FOR FRONT-LINE TREATMENT OF YOUNGER ADULTS WITH PH-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): INTERIM ANALYSIS OF THE GRAAPH-2014 TRIAL
EHA Learning Center, Yves Chalandon, 215254
PEDIATRIC PATIENTS WITH ACUTE LEUKEMIA AND MLL REARRANGEMENT SHOW A DISTINCTIVE EXPRESSION PATTERN OF HISTONE DEACETYLASES
EHA Learning Center, Nerea Vega-Garcia, 215255
PHARMACOLOGIC INHIBITION OF CELLULAR METABOLIC PROCESSES IMPACTED BY AGING SENSITIZE ACUTE MYELOID LEUKEMIA (AML) CELLS TO THE NOVEL LIPOATE DERIVATIVE CPI-613
EHA Learning Center, Timothy Pardee, 215270
GENOMIC CHARACTERIZATION OF DIAGNOSTIC AND REFRACTORY/RELAPSED ACUTE MYELOID LEUKEMIA SAMPLES THROUGH A NEXT GENERATION SEQUENCING (NGS) PANEL OF 62 GENES
EHA Learning Center, Diego Carbonell, 215271
HEMATOPOIETIC FUNCTIONS OF R396Q AND R204X GATA2 MUTANTS SUGGEST DISTINCT MECHANISMS LEADING TO THE GATA2 SYNDROME
EHA Learning Center, Eric DELABESSE, 215272
THE CALCIUM BINDING PROTEIN S100A8/S100A9 COMPLEX IS ASSOCIATED WITH DRUG RESISTANCE IN ACUTE MYELOID LEUKEMIA
EHA Learning Center, Riikka Karjalainen, 215286
A HIGH RISK PEDIATRIC AML SUBTYPE PRESENTS A DIAGNOSTIC CHALLENGE-A REPORT FROM THE CHILDREN’S ONCOLOGY GROUP AAML0531 STUDY
EHA Learning Center, Timothy P Singleton, 215288
TARGETED COMBINATION THERAPY AGAINST ONCOGENIC PI3K/AKT/MTOR AND NFKB SIGNALLING PATHWAYS USING ACUTE MYELOID LEUKEMIA AS A CANCER MODEL
EHA Learning Center, Montserrat Estruch, 215289
SINGLE CENTRE REAL-LIFE EXPERIENCE OF HYPOMETHYLATING AGENTS WITH OR WITHOUT DLI AS SALVAGE THERAPY FOR ACUTE MYELOID LEUKEMIA RELAPSING AFTER ALLOGENEIC STEM CELL TRANSPLANTATION.
EHA Learning Center, Davide Lazzarotto, 215303
CONSOLIDATION CHEMOTHERAPY PREVENTS RELAPSE BY INDIRECTLY REGULATING BONE MARROW ADIPOGENESIS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA
EHA Learning Center, Hanyan Liu, 215304
CONTINUING ENASIDENIB TREATMENT FOR PATIENTS WITH MUTANT-IDH2 RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (R/R AML) WITH STABLE DISEASE MAY RESULT IN IMPROVED RESPONSES AND SURVIVAL OVER TIME
EHA Learning Center, Eytan M. Stein, 215305
INTRA-PATIENT DOSE-ESCALATION STUDY OF CRENOLANIB MAINTENANCE THERAPY IN PATIENTS WITH FLT3 MUTANT AML WHO HAD UNDERGONE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT (ALLO-HSCT)
EHA Learning Center, Betul Oran, 215319
CONSOLIDATION THERAPY WITH PONATINIB IN COMBINATION WITH CYTARABINE IN PATIENTS FOR FLT3-ITD ACUTE MYELOID LEUKEMIA IN FIRST COMPLETE REMISSION.
EHA Learning Center, Philippe Rousselot, 215320
PHASE 1/1B STUDY OF PEVONEDISTAT (PEV) AS A SINGLE AGENT OR COMBINED WITH AZACITIDINE (AZA) IN EAST ASIAN PATIENTS (PTS) WITH ACUTE MYELOID LEUKEMIA (AML) OR MYELODYSPLASTIC SYNDROME (MDS)
EHA Learning Center, SHANG-JU WU, 215321
ACALABRUTINIB IN COMBINATION WITH THE PI3Kδ INHIBITOR ACP-319 IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL MALIGNANCIES.
EHA Learning Center, Paul M. Barr, 215335
TIME TO RELAPSE OF MANTLE CELL LYMPHOMA AFTER INTENSIVE HIGH DOSE CYTARABINE CONTAINING REGIMENS DEFINES PATIENTS RISK FOR DEATH: AN ANALYSIS FROM CENTERS OF THE FONDAZIONE ITALIANA LINFOMI
EHA Learning Center, Carlo Visco, 215336
CC-122-DLBCL-001: PHASE IB STUDY OF CC-122 PLUS RITUXIMAB IN PATIENTS WITH CHEMO-REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
EHA Learning Center, Vincent Ribrag, 215337
THE ADDITION OF ROMIDEPSIN TO CHOEP FOLLOWED BY HIGH-DOSE CHEMOTHERAPY AND TRANSPLANTATION IS FEASIBLE IN UNTREATED PERIPHERAL T-CELL LYMPHOMAS: RESULTS OF PHASE IB FIL-PTCL13
EHA Learning Center, Annalisa Chiappella, 215351
A PHASE I, MULTICENTER, OPEN-LABEL DOSE-ESCALATION STUDY OF CC-122, A NOVEL CEREBLON-MODULATING AGENT, IN ADULT JAPANESE PATIENTS WITH ADVANCED NON-HODGKIN LYMPHOMA OR SOLID TUMOR
EHA Learning Center, Kazuhito Yamamoto, 215352
GLOBAL LONGITUDINAL STRAIN (2D-GLS) IN LYMPHOMA PATIENTS TREATED WITH CHEMOTHERAPY +/- MEDIASTINAL RADIOTHERAPY: EARLY SUBCLINICAL CARDIOTOXICITY IN THE CARDIOCARE PROSPECTIVE OBSERVATIONAL STUDY.
EHA Learning Center, Barbara Botto, 215353
THALIDOMIDE USE IN HEREDITARY HEMORRHAGIC TELANGIECTASIA: A RETROSPECTIVE EVALUATION OF THE PATIENTS
EHA Learning Center, Mehmet Baysal, 215367
DIAGNOSIS AND MANAGEMENT OF ACQUIRED VON WILLEBRAND DISEASE. A SINGLE CENTER EXPERIENCE
EHA Learning Center, Cristina Santoro, 215368
CONGENITAL FXIII DEFICIENCY IN PAKISTAN
EHA Learning Center, Munira Borhany, 215369
MANAGEMENT OF PATIENTS WITH SEVERE APLASTIC ANAEMIA WHO ARE REFRACTORY TO PLATELET TRANSFUSIONS USING LEUKOCYTE CONCENTRATES
EHA Learning Center, jiali Huo, 215383
IRON OVERLOAD AND MANAGEMENT IN PATIENTS WITH DIAMOND BLACKFAN ANEMIA
EHA Learning Center, Sule Unal, 215384
HIGHER RATE OF DYSMORPHIC FEATURES IN PATIENTS WITH DIAMOND BLACKFAN ANEMIA
EHA Learning Center, Sule Unal, 215385
DETIN: OVERCOMING TUMOR IN NORMAL CONTAMINATION.
EHA Learning Center, Amaro Taylor-Weiner, 215400
TRACKING THE MINOR CLONES IN OLIGOCLONAL CHRONIC LYMPHOCYTIC LEUKEMIA USING HIGH-THROUGHPUT IMMUNOPROFILING
EHA Learning Center, Kamila Stranska, 215401
SINGLE CELL ABNORMALITIES ON CLASSIC G-BANDING ANALYSIS OF CHRONIC LYMPHOCYTIC LEUKEMIA: A NEW DIAGNOSTIC AND BIOLOGICAL CHALLENGE?
EHA Learning Center, Anastasia Athanasiadou, 215402
EXPRESSION OF ANTIGENS INVOLVED IN THE FORMATION OF AN IMMUNOLOGICAL SYNAPSE IN CHRONIC LYMPHOCYTIC LEUKEMIA
EHA Learning Center, Yulia Davydova, 215416
IDENTIFICATION OF NEWLY DIAGNOSED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA AT HIGH RISK OF INFECTION OR TREATMENT THROUGH MACHINE LEARNING ALGORITHMS
EHA Learning Center, Carsten Niemann, 215417
HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN RELATION TO RESPONSE TO FIRSTLINE THERAPY AND SUBSEQUENT TREATMENTS – A METAANALYSIS OF HRQOL MEASURED IN PHASE III TRIALS OF THE GERMAN CLL STUDY GROUP
EHA Learning Center, Nadine Kutsch, 215418
TREATMENT-FREE REMISSION AFTER SECOND-STOP OF IMATINIB THERAPY IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE
EHA Learning Center, Sukjoong Oh, 215433
TWO YEARS OF THERAPY WITH MATINIB GENERICS IN CHRONIC MYELOID LEUKEMIA; A REPORT FROM THE POLISH ADULT LEUKEMIA GROUP (PALG) IMATINIB GENERICS REGISTRY
EHA Learning Center, Tomasz , 215434
MAINTENANCE THERAPY WITH DASATINIB ADMINISTRATED EVERY OTHER DAY IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA
EHA Learning Center, Clemence Loiseau, 215435
PREVALENCE AND PREDICTORS OF LIVER FIBROSIS EVALUATED BY VIBRATION CONTROLLED TRANSIENT ELASTOGRAPHY (FIBROSCAN®) IN ADULT PATIENTS WITH TYPE 1 GAUCHER DISEASE
EHA Learning Center, Maria Domenica Cappellini, 215450
PREVALENCE AND CLINICAL SIGNIFICANCE OF SMALL PNH CLONES IN PATIENTS WITH PRIMARY AUTOIMMUNE HEMOLYTIC ANEMIA
EHA Learning Center, Bruno Fattizzo, 215451
COMBINATION TREATMENT OF RITUXIMAB, CYCLOPHOSPHAMIDE, AND DEXAMETHASONE FOR WARM AUTOIMMUNE HEMOLYTIC ANEMIA
EHA Learning Center, Caroline Piatek, 215452
THE COMBINATION OF CD19/BCMA-DIRECTED CART CELLS INDUCED THERAPEUTIC RESPONSE AND REVERSIBLE COMPARTMENTAL CYTOKINE RELEASE SYNDROME CONFINED TO CEREBRAL REGION IN A PATIENT WITH CNS MULTIPLE MYELOMA
EHA Learning Center, Caixia Li, 215466
INITIAL EXPERIENCE IN US COMMERCIAL MANUFACTURING OF TISAGENLECLEUCEL, A CHIMERIC ANTIGEN RECEPTOR (CAR)-T CELL THERAPY FOR PEDIATRIC RELAPSED/REFRACTORY B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA
EHA Learning Center, Brian Majors, 215467
ALLOGENEIC NK CELLS AND THEIR USE IN CLINICAL TRIALS
EHA Learning Center, Ludovit Bielik, 215468
BRENTUXIMAB VEDOTIN WITH CHEMOTHERAPY FOR STAGE III OR IV HODGKIN LYMPHOMA: IMPACT OF CYCLE 2 PET RESULT ON MODIFIED PROGRESSION-FREE SURVIVAL
EHA Learning Center, Robert Chen, 215482
BENDAMUSTINE IN COMBINATION WITH NIVOLUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA AFTER FAILURE OR SUBOPTIMAL RESPONSES TO NIVOLUMAB THERAPY.
EHA Learning Center, Kirill Lepik, 215483
NIVOLUMAB RESTORES SENSITIVITY TO CHEMOTHERAPY IN CHEMOREFRACTORY CLASSICAL HODGKIN LYMPHOMA PATIENTS
EHA Learning Center, Carmelo Carlo-Stella, 215484
IBRUTINIB MONOTHERAPY IN SYMPTOMATIC, TREATMENT-NAIVE PATIENTS WITH WALDENSTROM’S MACROGLOBULINEMIA.
EHA Learning Center, Steven Treon, 215498
CLINICAL OUTCOME OF PATIENTS WITH LOCALIZED PRIMARY OCULAR ADNEXAL MUCOSA-ASSOCIATED LYMPHOID TISSUE (MALT) LYMPHOMA (OAL): LONG-TERM FOLLOW-UP RESULTS FROM A SINGLE-INSTITUTION OBSERVATIONAL STUDY.
EHA Learning Center, Ritsuko Nakai, 215499
CD5-NEGATIVE MANTLE CELL LYMPHOMA: A DIAGNOSTIC CHALLENGE IN LEUKEMIC NON-NODAL CASES EXCLUSIVELY DIAGNOSED IN PERIPHERAL BLOOD
EHA Learning Center, Sara Montesdeoca Romero, 215500
Clinical and microbiological profile of bloodstream infections in patients with hematological malignancies and febrile neutropenia (PS 1210).
EHA Learning Center, Haydee Bernard, 215515
VACCINATION IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES OR SOLID TUMORS – GUIDELINE OF THE INFECTIOUS DISEASES WORKING PARTY (AGIHO) OF THE GERMAN SOCIETY FOR HEMATOLOGY AND MEDICAL ONCOLOGY (DGHO)
EHA Learning Center, Sibylle Mellinghoff, 215517
CHARACTERISTICS OF HEMATOLOGICAL PATIENTS WITH BLOOD CULTURES PROVEN SEPSIS – EXPERIENCE OF ONE CENTER
EHA Learning Center, Karla Jakobac, 215518
PANCREATIC IRON LOADING IN EMOGLOBINOPATHIES.
EHA Learning Center, Alessia Pepe, 215532
CHR AND %HYPO: BETTER METHODS FOR ASSESSING FUNCTIONAL IRON DEFICIENCY IN CHRONIC KIDNEY DISEASE?
EHA Learning Center, Laura Smith, 215533
GROWING IMPORTANCE OF FLOW CYTOMETRY (FCM) IN THE DIAGNOSTICS OF MYELODYSPLASTIC SYNDROMES: SENSITIVITY AND SPECIFICITY OF THE UP-TO-DATE SCORING SYSTEMS UNDER SPECIAL CONSIDERATION OF THE NEW IFSCORE
EHA Learning Center, Uta OELSCHLAEGEL, 215534
AN OPEN-LABEL PHASE 1 STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF DURVALUMAB IN PATIENTS WITH MYELODYSPLASTIC SYNDROME AFTER TREATMENT WITH HYPOMETHYLATING AGENTS
EHA Learning Center, Guillermo Garcia-Manero, 215548
SINGLE AGENT TALACOTUZUMAB IN ELDERLY HIGH-RISK MDS OR AML PATIENTS FAILING HYPOMETHYLATING AGENTS – RESULTS OF THE SAMBA STUDY BY THE EMSCO NETWORK
EHA Learning Center, Uwe Platzbecker, 215549
BI-ALLELIC LOSS OF FAM46C BY CRISPR/CAS9 SYSTEM ENHANCES MYELOMA CELL GROWTH
EHA Learning Center, KANASUGI JO, 215565
MOLECULAR SEGMENTATION OF MULTIPLE MYELOMA BY INTEGRATIVE MULTI-OMICS ANALYSIS
EHA Learning Center, Maria Ortiz Estevez, 215566
MULTIPLE MYELOMA: SINGLE PLARFORM ABSOLUTE COUNT OF CIRCULATING PLASMA CELLS AT DIAGNOSIS CORRELATE WITH POOR PROGNOSIS PARAMETERS.
EHA Learning Center, Vittorio Emanuele Muccio, 215581
MULTIPLE MYELOMA PATHOGENESIS: THE ROLE OF JUNB IN BONE MARROW ANGIOGENESIS
EHA Learning Center, Stefano Malvestiti, 215582
WEEKLY CARFILZOMIB, LENALIDOMIDE, AND DEXAMETHASONE (KRD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): A PHASE 1B STUDY
EHA Learning Center, Noa Biran, 215597
EXTENDED 5-Y FOLLOW-UP OF PHASE 3 ELOQUENT-2 STUDY: ELOTUZUMAB PLUS LENALIDOMIDE/DEXAMETHASONE VS LENALIDOMIDE/DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
EHA Learning Center, Katja C Weisel, 215598
REAL-WORLD OUTCOMES IN TRANSPLANT INELIGIBLE NDMM PATIENTS: RESULTS FROM A LARGE UK COHORT
EHA Learning Center, FAOUZI DJEBBARI, 215613
BONE MARROW PLASMA CELL INFILTRATION IN LIGHT-CHAIN AMYLOIDOSIS: IMPACT ON ORGAN INVOLVEMENT AND OUTCOME
EHA Learning Center, Luis Gerardo Rodríguez-Lobato, 215614
A PHASE 1B STUDY USING THE COMBINATION OF SELINEXOR, DARATUMUMAB, AND DEXAMETHASOME IN MULTIPLE MYELOMA PATIENTS PREVIOUSLY EXPOSED TO PROTEASOME INHIBITORS AND IMMUNOMODULATORY DRUGS
EHA Learning Center, Cristina Gasparetto, 215629
A REAL WORLD RETROSPECTIVE ANALYSIS OF EXTRAMEDULLARY DISEASE FROM BALKAN MYELOMA STUDY GROUP AND BARCELONA UNIVERSITY: CLINICAL FEATURES AND OUTCOME
EHA Learning Center, Meral Beksac, 215630
IN VIVO INHIBITION OF JAKS IN MYELOFIBROSIS IMPROVES MONOCYTES DIFFERENTIATION AND REACTIVATES PRO-INFLAMMATORY RESPONSE IN INFECTION-STIMULATED MONOCYTES
EHA Learning Center, Lucia Catani, 215645
POLO-LIKE KINASE-1, AURORA KINASE A AND WEE1: NEW THERAPEUTIC TARGETS IN SYSTEMIC MASTOCYTOSIS
EHA Learning Center, Manuela Mancini, 215646
FAMILIAL MYELOPROLIFERATIVE NEOPLASMS: A SINGLE-INSTITUTION ANALYSIS OF 22 FAMILIES
EHA Learning Center, Margherita Maffioli, 215661
THROMBOEMBOLIC EVENTS AFTER DIAGNOSIS OF POLYCYTHAEMIA VERA IN A SINGLE CENTER POPULATION
EHA Learning Center, Natalia Curto-Garcia, 215662
CLINICAL, PATHOLOGICAL AND MOLECULAR STUDY OF 46 PATIENTS WITH A DIAGNOSIS OF CD5-POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA.
EHA Learning Center, Vincent Allain, 215678
THE NOVEL TUMOR SUPPRESSOR SAMHD1 IS FREQUENTLY DOWNREGULATED AND CORRELATES WITH GERMINAL CENTER PHENOTYPE IN DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
EHA Learning Center, Ioanna Xagoraris, 215679
FEATURES OF PRN1008, A BRUTON’S TYROSINE KINASE INHIBITOR, IN CLINICAL DEVELOPMENT FOR IMMUNE THROMBOCYTOPENIC PURPURA
EHA Learning Center, Steven Gourlay, 215695
ATRA CORRECTS IMPAIRED MACROPHAGE FUNCTION IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA THROUGH A20/NLRP3 SIGNALING PATHWAY
EHA Learning Center, Yun He, 215696
STUDIES ON PLATELET FUNCTION IN A GROUP OF CLL PATIENTS DURING THE FIRST YEAR OF IBRUTINIB TREATMENT
EHA Learning Center, Bozena Sokolowska, 215712
VALIDATION OF THE PLASMIC SCORE FOR THROMBOTIC MICROANGIOPATIES IN A SINGLE UNVERSITY HOSPITAL
EHA Learning Center, Maria del Carmen Ballester Ruiz, 215713
CLARITHROMYCIN ADDED TO THE VCD REGIMEN CAUSES REDUCED HEALTH-RELATED QUALITY OF LIFE IN MULTIPLE MYELOMA PATIENTS
EHA Learning Center, Lene Kongsgaard Nielsen, 215728
RELINF PROJECT: PROSPECTIVE EPIDEMIOLOGICAL REGISTRY OF LYMPHOID NEOPLASMS IN SPAIN, ON BEHALF OF GELTAMO GROUP
EHA Learning Center, M Bastos Oreiro, 215729
CORRELATION BETWEEN HEMOLYSIS AND HYPERCOAGULABILITY MARKERS AND EFFECTS OF HYDROXYUREA THERAPY IN SICKLE CELL PATIENTS
EHA Learning Center, Maria de Fátima Sonati, 215745
INFLUENCE OF BCL11A POLYMORPHYSMS ON FETAL HEMOGLOBIN LEVELS AND HAEMOLYSIS MARKERS IN SICKLE CELL ANEMIA PEDIATRIC PATIENTS NOT RECEIVING HYDROXYUREA
EHA Learning Center, Dalila Luciola ZANETTE, 215746
ROLE OF IFN-GAMMA IN IMMUNE-MEDIATED GRAFT FAILURE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
EHA Learning Center, Pietro Merli, 215761
EFFECTS OF POST-AUTO-HSCT MRI BONE MARROW LESIONS ON PROGRESSION-FREE SURVIVAL IN PATIENTS WITH MM
EHA Learning Center, Maxim Solovev, 215762
SECOND TRANSPLANT FOR PRIMARY GRAFT FAILURE , FOLLOWING HAPLOIDENTICAL GRAFTS WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE
EHA Learning Center, SABRINA GIAMMARCO, 215777
SUBPOPULATIONS OF MONOCYTES AND B REGULATORY CELLS IN PATIENTS WITH CHRONIC GRAFT-VERSUS-HOST DISEASE
EHA Learning Center, Drazen Pulanic, 215778
THE RELATIONSHIP BETWEEN SELECTIVE PRE-TRANSPLANTATION IMMUNE PARAMETERS AND EARLY INFECTIONS IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES UNDERGOING ASCT – PRELIMINARY REPORT
EHA Learning Center, Agnieszka Szymczyk, 215793
SELECTIVE HSC-ABLATION USING ANTI-CD117 ANTIBODY DRUG CONJUGATE ENABLES SAFE AND EFFECTIVE AUTOLOGOUS AND ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
EHA Learning Center, Agnieszka Czechowicz, 215794
ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA AND ACUTE PANCREATITIS: VARIABLE AND RECIPROCAL PATHOPHYSIOLOGIC RELATIONSHIPS
EHA Learning Center, Qian (Janie) Qin, 215810
EVALUATION OF LUPUS ANTICOAGULANT TESTING: A THREE YEAR EXPERIENCE
EHA Learning Center, Isabel Izquierdo García, 215811
MASSIVE TRANSFUSION PROTOCOLS - FRIEND OR FOE ?
EHA Learning Center, Moon Ley Tung, 215826
PLATELET-DERIVED MICROPARTICLES; THE EXPRESSION PROPERTIES AND POTENSIAL AS A SUBSTITUTE FOR PLATELETS
EHA Learning Center, Shima Azadpour, 215827
MIR-497~195 CLUSTER IS ASSOCIATED WITH FAVORABLE OUTCOME AND HAS A TUMOR SUPPRESSIVE FUNCTION IN PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA
EHA Learning Center, Elena Boldrin, 215890
MICRORNA-142 IS AN ESSENTIAL REGULATOR OF B CELL DEVELOPMENT AND MALIGNANT TRANSFORMATION
EHA Learning Center, Wei-Le Wang, 215891
INTESTINAL COLONIZATION BY MULTIDRUG-RESISTANT GRAM-NEGATIVE PATHOGENS IN HEMATOLOGICAL PATIENTS: REAPPRAISAL OF SELECTIVE ORAL DECONTAMINATION
EHA Learning Center, Igor Stoma, 215906
EMERGING MICROBIAL RESISTANCE IN FEBRILE NEUTROPENIA- IS IT HIGH TIME TO EVALUATE QUALITY CONTROL MEASURES?
EHA Learning Center, Nida Anwar, 215907
INCREASED PLATELET RESPONSE TO ENDOGENOUS AGONISTS, IN PRE-DIABETIC C57BL/6 MICE
EHA Learning Center, Zibusiso Mkandla, 215922

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings